Why the study?
Does spironolactone reduce AASI in essential hypertensive patients?
Does spironolactone reduce AASI in essential hypertensive patients?
Spironolactone reduces arterial stiffness (measured by AASI) in patients with essential hypertension over 6 months.
Hypothesis-generating for arterial stiffness reduction in hypertension; leaves open effects on clinical outcomes.
In this short communication we report complementary data to previous ones, which confirm the effects of spironolactone in reducing AASI, a marker of arterial stiffness, in essential hypertensive patients after 6 months of treatment.
No takes yet. Share an insight, caveat, or question.
Bendersky et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: